Literature DB >> 18500231

Inhibitory B7-family molecules in the tumour microenvironment.

Weiping Zou1, Lieping Chen.   

Abstract

The B7 family consists of activating and inhibitory co-stimulatory molecules that positively and negatively regulate immune responses. Recent studies have shown that human and rodent cancer cells, and stromal cells and immune cells in the cancer microenvironment upregulate expression of inhibitory B7 molecules and that these contribute to tumour immune evasion. In this Review, we focus on the roles of these B7 molecules in the dynamic interactions between tumours and the host immune system, including their expression, regulation and function in the tumour microenvironment. We also discuss novel therapeutic strategies that target these inhibitory B7 molecules and their signalling pathways to treat human cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500231     DOI: 10.1038/nri2326

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  641 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

4.  PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.

Authors:  Victor Peña-Cruz; Sean M McDonough; Felipe Diaz-Griffero; Christopher P Crum; Ruben D Carrasco; Gordon J Freeman
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

5.  Adaptive resistance: a tumor strategy to evade immune attack.

Authors:  Sheng Yao; Lieping Chen
Journal:  Eur J Immunol       Date:  2013-02-04       Impact factor: 5.532

Review 6.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

Review 7.  Immune checkpoint inhibitors in gastrointestinal malignancies.

Authors:  Vishal Jindal
Journal:  J Gastrointest Oncol       Date:  2018-04

Review 8.  Mast cells as regulators of adaptive immunity to tumours.

Authors:  A Wasiuk; V C de Vries; K Hartmann; A Roers; R J Noelle
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

Review 9.  Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Authors:  Kim A Reiss; Patrick M Forde; Julie R Brahmer
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

10.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.